Emergent BiosolutionsEBS
Market Cap: $394M
About: Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Employees: 1,600
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
120% more capital invested
Capital invested by funds: $94.4M [Q1] → $207M (+$113M) [Q2]
71% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 28
17% more funds holding
Funds holding: 120 [Q1] → 140 (+20) [Q2]
3% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 36
13.3% less ownership
Funds ownership: 71.34% [Q1] → 58.04% (-13.3%) [Q2]
47% less call options, than puts
Call options by funds: $3.09M | Put options by funds: $5.83M
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Rodman & Renshaw | 113%upside $16 | Buy Initiated | 22 Aug 2024 |
Benchmark Robert Wasserman 50% 1-year accuracy 22 / 44 met price target | 6%upside $8 | Buy Reiterated | 16 Aug 2024 |
Benchmark Robert Wasserman 50% 1-year accuracy 22 / 44 met price target | 6%upside $8 | Buy Reiterated | 9 Aug 2024 |
Benchmark Robert Wasserman 50% 1-year accuracy 22 / 44 met price target | 6%upside $8 | Buy Reiterated | 3 Jul 2024 |
Benchmark Robert Wasserman 50% 1-year accuracy 22 / 44 met price target | 6%upside $8 | Buy Reiterated | 2 Jul 2024 |
Financial journalist opinion
Based on 17 articles about EBS published over the past 30 days